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Abstract
Background—Congenital muscular dystrophies (CMDs) are a genetically and clinically 
heterogeneous group of neuromuscular disorders. Several genes encoding extracellular matrix, 
nuclear envelope, sarcolemmal proteins and glycosylation enzymes have been implicated in 
CMDs. The large overlap of clinical presentations due to mutations in different genes poses a 
challenge for clinicians in determining disease etiology for each patient.
Objective—We investigated the use of whole exome sequencing (WES) in identifying the 
genetic cause of disease in 5 CMD patients from 3 families who presented with highly similar 
clinical features, including early-onset rapidly progressive weakness without brain or eye 
abnormalities.
Methods—Whole exome sequencing was performed on DNA from affected individuals. 
Potential functional impacts of mutations were investigated by immunostaining on available 
muscle biopsies.
Results—Pathogenic mutations in 3 different genes, DYSF, FKTN, and ISPD were identified in 
each family. Mutation in DYSF led to absence of dysferlin protein in patient muscle. Mutations in 
ISPD led to impaired ISDP function, as demonstrated by deficiency of α-dystroglycan 
glycosylation in patient muscle.
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Conclusions—This study highlights the benefit of unbiased genomic approaches in molecular 
diagnosis of neuromuscular disorders with high clinical heterogeneity, such as the phenotypes 
observed in our patients. Our results suggest that dysferlin deficiency should be in the differential 
diagnosis of congenital and rapidly progressive muscular dystrophy, and therefore dysferlin 
antibody should be in the standard immunohistochemistry panel for muscle biopsies in cases with 
suspected CMD.
Keywords
Muscular dystrophies; DYSF protein human; Dysferlinopathy; FKTN protein human; ISPD protein 
human; neuromuscular diseases; genetic testing
INTRODUTION
Congenital muscular dystrophies (CMDs) are a group of genetically heterogeneous 
neuromuscular disorders that present at birth or early infancy with hypotonia and muscle 
weakness [1]. The broad phenotypic spectrum and large overlap of clinical presentations 
resulting from different gene mutations pose a challenge for clinicians in making a diagnosis 
and determining the underlying genetic cause for each patient. Therefore, an unbiased 
genetic testing approach may be beneficial to determine disease etiology, guide patient 
clinical care and aid family counseling.
We report 5 affected children from 3 unrelated families who presented with very similar 
clinical features, including early-onset generalized weakness, severely elevated creatine 
kinase (CK) levels, and rapid progression of disease. Using whole exome sequencing 
(WES), we identified mutations in 3 different genes in the 3 families, including novel 
mutations, in the dysferlin (DYSF), fukutin (FKTN), and isoprenoid synthase domain-
containing protein (ISPD) genes. Our results highlight the benefit of WES as a diagnostic 
tool for neuromuscular diseases with wide clinical spectrum and high genetic heterogeneity, 
such as the phenotype observed in our patients.
MATERIALS AND METHODS
Standard protocol approvals and patient consents
This study was approved by the institutional review board of Boston Children’s Hospital. 
Written informed consent was obtained from all participants.
Molecular studies
Whole exome sequencing of DNA from probands and related individuals was performed by 
the IDDRC Core Next-Gen Sequencing Facility of Boston Children’s Hospital and Harvard 
Medical School, in collaboration with Axeq Technologies. Samples were enriched for 
exomic sequences using the Illumina Exome Enrichment protocol and captured libraries 
were sequenced using Illumina HiSeq 2000 Sequencers. The reads were mapped to the 
human genome assembly UCSC hg19 using Burrows-Wheeler Alignment (BWA version 
0.5.8, http://bio-bwa.sourceforge.net/). Single nucleotide polymorphisms and small 
insertions/deletions were called with SAMtools (version 0.1.7, http://
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samtools.sourceforge.net/). The annotated variants were filtered against variations reported 
on dbSNP132, the 1000 Genomes project November 2010 edition, and the NHLBI Exome 
Sequencing Project (http://evs.gs.washington.edu/EVS/) databases. Computational tools 
SIFT [2] and PolyPhen [3] were used to predict the impact of missense, while MaxEntScan 
[4] and NNSplice [5] were used to predict the impact of splice variants. All reported 
mutations were confirmed by Sanger sequencing in the patients and carrier parents.
Immunostaining on muscle biopsies
Muscle histology was examined using standard immunohistochemical staining. Frozen 
muscle sections from Patient C were fixed in ice-cold acetone for 10 minutes, followed by 
immunostaining with IIH6 antibody.
RESULTS
Case reports
We tested 3 Turkish families with clinical diagnoses of congenital muscular dystrophy by 
whole exome sequencing.
Two siblings from a consanguineous family (Family A), 14 and 11 years old, presented at 4 
months and 6 months of age, respectively with hypotonia and delayed motor milestones. CK 
levels of the older sibling (a girl) were 728 and 4909 IU/L at 2 and 6 years of age, 
respectively. She became ambulant at age 2.5 years but lost the ability to walk at 8 years. 
She developed hip and ankle contractures gradually starting from age 3. Examination at 11 
years revealed muscle power of 4/5 for neck flexors, 3+/5 for deltoids, 3+/5 for triceps, 2/5 
for quadriceps, and 2/5 for hamstrings. Patients did not have intellectual disability in 
neurocognitive evaluation. Clinical presentation of the younger affected sibling (a boy) was 
relatively milder. Despite early onset of hypotonia by 6 months, he continues to walk, albeit 
with difficulty at age 11. Currently he cannot rise from the floor.
The proband from Family B presented at 8 months of age with hypotonia and delayed motor 
milestones. CK levels were 2675 IU/L at 1.5 years and 4025 IU/L at 3 years of age. He 
became ambulant at age 3.5 years and is currently able to walk slowly at 6 years of age. 
Cranial MRI was normal. Patient did not have intellectual disability in neurocognitive 
evaluation.
Both affected siblings from Family C presented at 4 months of age with hypotonia and 
delayed motor milestones. The older sibling is currently nonambulant at 5 years of age. He 
can barely bear weight on legs. His CK levels were 4581 and 6640 IU/L at age 1.5 and 3.5 
years, respectively. Cranial MRI was normal. Patient did not have intellectual disability in 
neurocognitive evaluation. His younger sibling who is 13 months old now has a maximum 
ability to sit without support.
Major clinical and muscle biopsy findings in the 5 patients are summarized in Table 1.
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Identification of mutations by WES
We used WES in the affected probands to determine the underlying genetic defects. Samples 
were sequenced individually. On average, 94% (range 93.3% to 94.3%) of target regions 
were covered, and 84.4% (range 82.8% to 86.2%) were covered more than 10X. Average 
median coverage of target regions was 37X (range 30X to 44X across samples). 96.4% of 
Ref-Seq coding exons were covered. On average, 20,223 (range 19,941 to 20,447) variants 
were identified in exonic regions. Variants that were absent from or were rare (minor allele 
frequency <0.1%) in control populations in dbSNP135, 1000 Genomes project (November 
2010 edition), and NHLBI Exome Sequencing Project databases, as well as 80 race-matched 
control chromosomes, were filtered in 82 genes that have been implicated in neuromuscular 
diseases, including all congenital myopathy, muscular dystrophy, and congenital myasthenia 
syndrome genes in the literature. We only report variants that were novel or rare in the 
control populations (<0.1% minor allele frequency that would be consistent with the 
prevalence of congenital muscular dystrophy) and either 1) were predicted to lead to absent 
or truncated protein, or 2) have previously been reported in other patients with muscle 
disease or 3) was in a recessive gene and confirmed to be in trans with a variant meeting one 
of the above-mentioned criteria. Variants that were rare in the general population but did not 
meet these criteria were classified as uncertain significance and are not reported.
A homozygous frameshift mutation in the dysferlin gene (DYSF): c.2779delG 
(p.Ala927LeufsX21) that alters the protein sequence beginning from amino acid 927 and is 
predicted to lead to a premature termination codon 21 amino acids downstream, was 
identified in the patients from Family A. This variant was confirmed to be heterozygous in 
the parents. The same variant has previously been reported in ten individuals with hyper-
CKemia who were asymptomatic until the second to third decade of life [6], three 
individuals with LGMD [7, 8], and two siblings with congenital muscular dystrophy who 
had normal or mildly elevated CK levels at ages 2 and 3 years [9]. The patients in our study 
had highly elevated CK levels at 2 years old. Arm muscles were preserved in patients 
described by Paradas et al. [9], however our patients had significant arm weakness. 
Interestingly, previously reported individuals carrying this variant were of Jews of the 
Caucasus, Iranian, and Spanish ethnicity, while the patients in our study were Turkish. Loss 
of function mutations of the DYSF gene are an established disease mechanism in limb girdle 
muscular dystrophy (LGMD) and Miyoshi myopathy, although patients with DYSF 
mutations typically have a later onset and milder disease compared to the patients in our 
study. Although other patients with earlier onset of muscle weakness have been described, 
our patients are unique in their presentation with highly elevated CK at an early age and 
involvement of all proximal muscle groups.
Two compound heterozygous missense variants were identified in the fukutin gene (FKTN): 
c.[915G>C];[920G>A] (p.[Trp305Cys];[Arg307Gln]) in the proband from Family B. The 
Arg307Gln variant has previously been reported in 2 patients with LGMD and a patient with 
CMD in compound heterozygous state with frameshift variants in FKTN and Trp305Cys 
variant has been reported in one patient with Muscle-Eye-Brain disease-Fukuyama 
Congenital Muscular Dystrophy phenotype [10, 11], supporting that they are pathogenic 
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variants. Variants were confirmed to be in trans by parental studies. Based on these reasons, 
these variants were determined to be pathogenic in this patient.
In both of the two affected siblings from Family C, we identified two novel compound 
heterozygous mutations in ISPD: one missense variant, c.458T>C (p.Ile153Thr) and one 
variant within the splice consensus sequence that was predicted to lead to altered splicing, c.
535-3C>G. Mutations were confirmed to be in trans by parental studies.
No other potentially pathogenic variants were identified in neuromuscular disease-related 
genes in the patients.
Confirming the impact of DYSF and ISPD mutations by immunostaining on muscle 
biopsies
To confirm the predicted impact of the DYSF mutation in Family A, dysferlin 
immunohistochemistry was performed and it revealed absence of dysferlin protein in the 
patient muscle (Fig. 1b).
Muscle biopsy was not available from the patient from Family B for α-dystroglycan staining 
and further studies.
α-Dystroglycan is hypoglycosylated in muscle biopsies from patients with ISPD mutations 
that cause loss of function of the protein [12, 13]. In order to test whether the ISPD 
mutations in Family C caused loss of function of the protein, we analyzed the glycosylation 
status of α-dystroglycan in the muscle biopsy using IIH6 antibody [12] (Fig. 1c). Staining 
with IIH6 antibody demonstrated lack of α-dystroglycan glycosylation in patient muscle, 
suggesting deficiency of ISPD function.
DISCUSSION
The five patients in our study all presented in the first year of life with rapidly progressing 
diffuse muscle weakness and highly elevated CK levels at an early age. In Family A, WES 
revealed a homozygous frameshift mutation in DYSF, a gene that is typically associated with 
a later onset LGMD phenotype and slower disease progression [9, 14, 15]. Reexamining the 
muscle biopsy in guidance of the genetic test results demonstrated that the mutation led to 
absence of dysferlin. The results from this case suggest that dysferlin deficiency should be in 
the differential diagnosis of congenital muscular dystrophy with significantly high CK at an 
early age. Thus, we suggest that dysferlin antibody should be used as standard in the 
immunohistochemistry panel for muscle biopsies in cases with suspected CMD.
We identified compound heterozygous mutations in FKTN and ISPD genes in Families B 
and C. FKTN and ISPD are typically associated with CMD or LGMD with variable brain 
and eye involvement [11, 12, 16, 17]. None of the patients in our study had cognitive or 
ocular abnormalities. Cranial MRI investigations were normal in all index cases. Patients 
from Family C with ISPD mutations presented with hypotonia and delayed motor milestones 
at 4 months of age, earlier than previously reported patients with ISPD mutations. α-
Dystroglycan deficiencies have a diverse clinical spectrum ranging from quite mild with a 
rather benign LGMD phenotype to severe weakness with profound eye and brain 
Ceyhan-Birsoy et al. Page 5
J Neuromuscul Dis. Author manuscript; available in PMC 2015 March 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
abnormalities. In the vast majority of cases, clinical prediction before genetic analysis may 
not be accurate. The usefulness of whole exome sequencing for diagnosing various 
Mendelian diseases have been demonstrated [18]. Our results highlight that unbiased 
genomic approaches may represent a powerful diagnostic tool for neuromuscular diseases 
with high clinical, pathological and genetic heterogeneity, such as the phenotype observed in 
our patients.
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Fig. 1. 
(a) Pedigrees of families A–C. Full black symbol, affected subjects. (b) Dysferlin 
immunohistochemistry in Patient A-II:1 muscle biopsy and healthy control muscle. (c) 
Immunostaining with IIH6 antibody for examining glycosylated α-dystroglycan in Patient 
C-II:1 and control muscle biopsies demonstrating absence of α-dystroglycan glycosylation 
in the patient muscle.
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